(Q33200753)

23 July 2017

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells (English)

1 reference

23 July 2017

1 reference

8

1 reference

23 July 2017

Joerg Bruenke

1

0 references

author name string

Barbara Fischer

2

1 reference

23 July 2017

Karin Barbin

3

1 reference

23 July 2017

Katja Schreiter

4

1 reference

23 July 2017

Yvonne Wachter

5

1 reference

23 July 2017

Kerstin Mahr

6

1 reference

23 July 2017

Fritz Titgemeyer

7

1 reference

23 July 2017

Matthias Peipp

9

1 reference

23 July 2017

Susan J Zunino

10

1 reference

23 July 2017

Roland Repp

11

1 reference

23 July 2017

Thomas Valerius

12

1 reference

23 July 2017

Georg H Fey

13

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

British Journal of Haematology

23 July 2017

1 reference

23 July 2017

125

1 reference

23 July 2017

2

1 reference

23 July 2017

167-179

1 reference

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

23 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Surrogate light chain-mediated interaction of a soluble pre-B cell receptor with adherent cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Bispecific human IgG by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

HLA class II antibodies in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Cytotoxicity mediated by human Fc receptors for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

The IgG Fc receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Affinity purification of tagged recombinant proteins using immobilized single chain Fv fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

New protein engineering approaches to multivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Bispecific antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Immunotherapeutic perspective for bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

Antibody-targeted immunotherapy for treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

T-cell activation and cytokine production via a bispecific single-chain antibody fragment targeted to blood-stage malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

A dimeric bispecific miniantibody combines two specificities with avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04893.X

10.1111/J.1365-2141.2004.04893.X

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference